Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies
Authors:
- A A RoppeltARA A Roppelt
- M S LebedkinaMLM S Lebedkina
- A A ChernovACA A Chernov
- T S KruglovaTKT S Kruglova
- O A MukhinaOMO A Mukhina
- Y D YukhnovskayaYYY D Yukhnovskaya
- F A SamedovaFSF A Samedova
- U A MаrkinaUMU A Mаrkina
- G V AndrenovaGAG V Andrenova
- A V KaraulovAKA V Karaulov
- M A LysenkoMLM A Lysenko
- D S FominaDFD S Fomina
Open Access
- 24 February 2023
- journal article
- research article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (1) , 78-84
Abstract
Background. Primary immunodeficiencies (PIDs), now known as inborn errors of immunity, are a group of inherited diseases caused by defects in the genes that control the immune response. Patients with PIDs have risks of developing a severe course and/or death in COVID-19. Passive immunization with long-acting monoclonal antibodies (MABs) to SARS-CoV-2 should be considered as pre-exposure prophylaxis in patients with PIDs. Tixagevimab/cilgavimab is a combination of MABs that bind to the SARS-CoV-2 spike protein. Aim. To evaluate the efficacy and safety of pre-exposure prophylaxis of new SARS-CoV-2 infection in PIDs with the combination of tixagevimab/cilgavimab. Materials and methods. Forty eight patients diagnosed with PIDs were included in the study. Median follow-up after drug administration was 174 days. The total number of confirmed coronavirus infections in patients with PIDs as well as 6 months before and after administration of MAT were assessed. Results. In the analyzed cohort, the overall incidence of COVID-19 from pandemic onset to MABs administration was 75% (36/48), with 31% (11/36) of over-infected patients having had the infection more than once. The incidence of COVID-19 immediately 6 months before the introduction of tixagevimab/cilgavimab was 40%. All patients who had COVID-19 after pre-exposure prophylaxis had a mild infection. The incidence of COVID-19 6 months after tixagevimab/cilgavimab administration significantly decreased compared to the incidence 6 months before administration (7 and 40%, respectively; p0.001). Conclusion. The use of tixagevimab/cilgavimab in patients with PIDs is effective as pre-exposure prophylaxis and reduces the risk of severe COVID-19.Keywords
This publication has 22 references indexed in Scilit:
- The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humansScience Translational Medicine, 2022
- Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktailNature Microbiology, 2021
- Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseasesAnnals of the Rheumatic Diseases, 2021
- Adverse COVID‐19 outcomes in immune deficiencies: Inequality exists between subclassesAllergy, 2021
- Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serumCell, 2021
- Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunityThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Coronavirus disease 2019 in patients with inborn errors of immunity: An international studyJournal of Allergy and Clinical Immunology, 2021
- COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping ReviewPathogens and Immunity, 2021
- COVID-19 INFECTION IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIESPediatria. Journal named after G.N. Speransky, 2020
- Impact of SARS-CoV-2 Pandemic on Patients with Primary ImmunodeficiencyJournal of Clinical Immunology, 2020